Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Research Will Push Forward Fight Against Leukaemia

25.10.2002


A project which aims to make laboratory-grown leukaemia cells change form and then be used to prime a patient’s own immune system to kill off malignant cells has begun in Edinburgh. If successful, the study could give clinicians a way of destroying residual leukaemic cells which are undetectable by microscope. The findings could be helpful in the treatment of acute myeloblastic leukaemia (AML), one of the most common forms of leukaemia in adults.



Although about 70% of patients with AML achieve complete remission of the disease after chemotherapy treatment, around half of the younger patients and the majority of elderly patients will ultimately relapse and die as a consequence of the disease. Three years survival rates are about 40% in younger patients and 10% in older patients.

This study, based at the John Hughes Bennett Laboratories at the University of Edinburgh, is led by haematologist Dr Marc Turner, who is Clinical Director of the Edinburgh and SE Scotland Blood Transfusion Centre.Dr Turner explained: “Relapse after initial successful chemotherapy is caused by residual leukaemic cells which are below a level which can be detected by microscope. Sometimes, they can cause the disease to restart, and it is much harder to treat the second time around. Methods of eliminating this minimal residual disease, such as bone marrow transplantation, can be successful but this form of treatment is only suitable for younger patients who are able to withstand the side effects of the treatment.”


“However, research work during the past few years has shown that it is possible to grow leukaemic cells in the laboratory and force them to change into a kind of immune cell called the dendritic cell. Dendritic cells are responsible for generating primary immune responses which can lead to the destruction of leukaemia cells.”

The work has now moved forward to the next phase of clinical trials, where patients with AML will donate bone marrow or blood cells before undergoing chemotherapy treatment. If they go into remission, their stored leukaemic cells will be specially cultured and changed into dendritic cells, which will be given back to the patient by injection. The dozen patients in the study will be carefully monitored for clinical and immunological responses. The trial will last for 12 to 18 months and is funded by the Leukaemia Research Fund and the Scottish National Blood Transfusion Service.

Dr David Grant, Scientific Director of the Leukaemia Research Fund, said: "The study of immunology - harnessing the body`s immune system to fight leukaemia - has advanced amazingly over the last 20 years. It is now crucial that we translate this knowledge into benefits for patients."

Linda Menzies | alfa
Further information:
http://www.ed.ac.uk

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>